Tumor immunotherapy: Mechanisms and clinical applications

被引:11
作者
Nong, Cheng [1 ]
Guan, Pengbo [1 ]
Li, Li [1 ]
Zhang, Huiyuan [1 ]
Hu, Hongbo [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Ctr Immunol & Hematol, Natl Clin Res Ctr Geriatr,State Key Lab Biotherap, Chengdu 610041, Peoples R China
[2] Chongqing Int Inst Immunol, Chongqing, Peoples R China
来源
MEDCOMM-ONCOLOGY | 2022年 / 1卷 / 01期
基金
中国国家自然科学基金;
关键词
CAR-T; immune checkpoint inhibition; immunotherapy; tumor microenvironment; INNATE LYMPHOID-CELLS; REGULATORY T-CELLS; METASTATIC NASOPHARYNGEAL CARCINOMA; PLATINUM-BASED CHEMOTHERAPY; CYTOKINE RELEASE SYNDROME; ACTIVATION GENE-3 LAG-3; NATURAL-KILLER-CELLS; IFN-GAMMA PRODUCTION; STAGE-III MELANOMA; OPEN-LABEL;
D O I
10.1002/mog2.8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy, which aims to enhance the functions of the host's immune system to eliminate invading pathogens and mutant cells, has been widely used for cancer treatment. Despite the enormous progress in immunotherapy, the efficiency of immunotherapy is urgent to be improved. The tumor microenvironment is composed of multiple types of infiltrating immune cells and stromal cells (such as endothelial cells, fibroblasts, and tumor cells), extracellular matrix, various cytokines, chemokines, growth factors, and metabolites, all of which play crucial roles in tumor progress, metastasis, relapse and the outcome of immunotherapy. Emerging evidence indicates a better understanding of the characteristics of the tumor microenvironment and its associated factors, which could lead to uncovering novel promising immunotherapy approaches. This review will summarize the current knowledge of heterogeneity and function of the immune cells in the tumor microenvironment, the current progress of immunotherapy focusing on immune checkpoint blockade and chimeric antigen T cell therapy, as well as the challenge and limitations of the current immunotherapy strategy. Overall, we aim to provide the conceptions of tumor immune microenvironment and application of immunotherapy, highlighting the potential strategies to improve tumor immunotherapy.
引用
收藏
页数:34
相关论文
共 50 条
  • [21] Immunotherapy for prostate cancer: is prostate an immune responsive tumor?
    Slovin, Susan F.
    CURRENT OPINION IN UROLOGY, 2016, 26 (06) : 529 - 534
  • [22] Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members
    Nagai, Hiroshi
    Oniki, Shuntaro
    Fujiwara, Susumu
    Yoshimoto, Takayuki
    Nishigori, Chikako
    IMMUNOTHERAPY, 2010, 2 (05) : 697 - 709
  • [23] Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
    Petty, Amy J.
    Owen, Dwight H.
    Yang, Yiping
    Huang, Xiaopei
    CANCERS, 2021, 13 (21)
  • [24] Tumor inherent interferons: Impact on immune reactivity and immunotherapy
    Brockwell, Natasha K.
    Parker, Belinda S.
    CYTOKINE, 2019, 118 : 42 - 47
  • [25] Natural killer cell-based cancer immunotherapy: from basics to clinical trials
    Shi, Yinghong
    Hao, Donglin
    Qian, Hui
    Tao, Zhimin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [26] Clinical Applications of Sublingual Immunotherapy
    Edwards, Thomas S.
    Wise, Sarah K.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2017, 50 (06) : 1121 - +
  • [27] Clinical cancer immunotherapy: Current progress and prospects
    Liu, Chenglong
    Yang, Mengxuan
    Zhang, Daizhou
    Chen, Ming
    Zhu, Di
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Neoantigens and their potential applications in tumor immunotherapy
    Fang, Xianzhu
    Guo, Zhiliang
    Liang, Jinqing
    Wen, Jiao
    Liu, Yuanyuan
    Guan, Xiumei
    Li, Hong
    ONCOLOGY LETTERS, 2022, 23 (03)
  • [29] Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape
    Wang, Zide
    Zhong, Hanlin
    Liang, Xiaohong
    Ni, Shilei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy
    Xie, Feng
    Liang, Rui
    Li, Dan
    Li, Bin
    ENGINEERING, 2019, 5 (01) : 132 - 139